Last week, DrugNews reported on new warnings from the FDA, European Medicines Agency and consumer group Institute for Safe Medication Practices that the popular diabetes drugs Invokana and Jardiance may increase the risk of ketoacidosis.
Since patients taking the drugs weren’t warned by the manufacturers of these deadly risks before, those diagnosed with ketoacidosis or kidney failure have begun an Invokana class action lawsuit in Canada and are coordinating special lawsuits here in the United States.
U.S. drug maker Pfizer announced this week that it was recalling tens of thousands of packages of infant and children’s Advil from store shelves in Canada, after analysis showed ingredient spoiling may lead to higher or lower dosages than intended.
The move comes during the heart of cold and flu season, when parents rely most on the medications to prevent family illness.
Amid increased warnings that the anti-nausea drug Zofran may be linked to serious birth defects when used during pregnancy, a federal panel last year created a special court for victims to seek compensation from the drug’s maker, GlaxoSmithKline.
In January, with hundreds of lawsuits already filed, Glaxo filed a request to have them thrown out of court before families had a chance to prove their case.
Experts have cautioned for years that new-generation oral blood thinners like Xarelto may have similar internal bleeding risks as warfarin, the traditional drug they were designed to replace.
And, recent studies show the risks for gastro-intestinal bleeding in particular may even be higher with Xarelto than warfarin.
Last May, the FDA warned consumers of a growing trend in nerve damage side effects from the popular antibiotics Levaquin, Avelox and Cipro. The news prompted calls for greater label warnings, an FDA public hearing, and the creation of a special court for victims who hadn’t been properly warned of the risks to file lawsuits.
Now, as the issue of antibiotic nerve damage risks gains greater exposure, the first Levaquin lawsuit has begun and a judge recently cleared the way for more victims to file claims.
Last month, the FDA made news when it announced new warnings about ketoacidosis and urinary tract infections would be added to three diabetes drugs of the SGLT2 class: Invokana, Jardiance and Farxiga.
Now, DrugNews reports that an increasing number of former Invokana patients are filing lawsuits against the maker of the drug, Janssen, after being subjected to ketoacidosis with little or no prior warning from the manufacturer.
After years of speculation that the popular anti-nausea drug Zofran may cause birth defects when prescribed for pregnancy morning sickness, a federal panel last year created a dedicated court for victims to file claims.
However, as the number of Zofran lawsuits have swelled to several hundred, the maker of the drug, GlaxoSmithKline (GSK), has filed a request to dismiss all claims in an effort to block the rights of families to recover damages.
Three novel oral anticoagulant medications – Pradaxa, Xarelto and Eliquis, have battled it out in recent years to grab their share of an estimated $6 billion blood thinning drug market once dominated by the generic drug warfarin.
And while each has promised it is safer and easier to use than warfarin, Pradaxa and Xarelto have been plagued by thousands of reports of patients suffering extended hospitalization or death from internal bleeding. So far, more than 5,000 lawsuits have surfaced alone for Pradaxa bleeding.
The US Food and Drug Administration (FDA) last week added health warnings to the labels of several popular drugs used to treat type-2 diabetes, after reports showed patients may be at risk of high blood acid levels and severe urinary tract infections.
The official label warnings follow a consumer warning issued by the FDA in May when the agency first learned of the ketoacidosis risks.
Patents who suffer from the heart irregularity atrial fibrillation, or who are at risk of blood clots after a major surgery, are often prescribed a blood thinner to reduce the risk of stroke.
Three oral blood thinners released between 2010 and 2012 - Pradaxa, Xarelto and Eliquis - have been fighting it out to gain a share of the estimated $6 billion anticoagulant market from warfarin, a drug used since the 1950s.
The U.S. Food and Drug Administration last week issued warnings for the new hepatitis medications, Technivie and Viekira Pak, after noticing an alarming trend of liver side effect reports. Patients taking either drug are cautioned to look for symptoms.
Both drugs are sold by Chicago-based pharmaceutical company Abbvie. Viekira Pak was approved by the FDA in December 2014 and Technivie was approved in July 2015, both for the treatment of hepatitis C.
Earlier this year, DrugNews reported on the growing concern among doctors that Zofran, a drug prescribed off-label for morning sickness in pregnant mothers, might raise the risk of serious birth defects.
Now, amid increased attention and a swell of lawsuits by families whose children have suffered birth defects, a federal panel has created a specialized Zofran multidistrict litigation court (MDL) to handle the cases.